Mini simpozij infrastrukturnih centrov Medicinske fakultete Univerze v Ljubljani, bo potekal 21. junija 2018 med 14:00 in 17:00 v srednji predavalnici na Medicinski fakulteti Univerze v Ljubljani na Korytkovi 2.
Taste of Genomics: the 70th anniversary of Prof. Radovan Komel and 13th CFGBC Scientific Symposium will take place from June 20th-21st 2018 at the University of Ljubljana, Faculty of Medicine, Slovenia.
Martin Kuiper1, Astrid Lægreid1, Åsmund Flobak1, Lodewyk Wessels2, Christine Sers3, Nils Bluethgen3, Emmanuel Barillot4, Alfonso Valencia5
1Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 2The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands, 3Charité University Medicine Berlin, Germany, 4Institut Curie, Paris, France, 5Spanish National Center for Cancer Research (CNIO), Madrid, Spain
COLOSYS: A systems approach to preventing drug resistance in colon cancer Colon cancer is a major cause of death. Current treatment involves chemotherapy combined with anti-EGFR or VEGF drugs and radiotherapy. Screening for biomarkers can indicate whether EGFR-inhibitors will be effective in patients, but otherwise biomarkers for personalizing patient treatment are scarce. The majority of patients develop resistance and succumb to the disease. We still have a poor understanding of how gene networks drive cancer, how they modulate response, and how they induce resistance to treatment. The COLOSYS consortium aims to develop in silico therapy response predictors that will allow precision medicine, based on patient-specific driver and resistance mechanisms. A high quality, open repository of data and knowledge (knowledge commons) is being assembled and used to construct computer models of the molecular networks that underlie cancerous cell proliferation. Whereas resistance against a single drug may quickly develop, the use of combinations of drugs may prove a significant advancement. We are therefore using logical model simulations to predict the effect of drugs, and in particular combinations of drugs, in cancer cell lines and patient tumors, and are going to test these predictions in cell lines as well as patient-derived cell cultures, organoids and mouse xenografts, and perform preliminary testing in patients. The combined computational, experimental and clinical testing will provide a thorough understanding of resistance mechanisms, and allow personalised treatment of colon cancer.
2006 - University of Ljubljana, Faculty of Medicine, Center for Functional Genomics and Bio-chips.